Realtime | Geld | Brief | Zeit |
---|---|---|---|
42,600 | 43,400 | 03.03. | |
42,700 | 43,300 | 03.03. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
LABORATORIOS FARMACEUTICOS ROVI Aktie jetzt für 0€ handeln | |||||
Di | LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria, both in Europe and the United States. | 1 | CNMV | ||
Di | LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria, both in Europe and the United States | 2 | CNMV | ||
24.02. | LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases the presentation related to the 2020 financial results | - | CNMV | ||
24.02. | LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases the press release related to the full year 2020 financial results | - | CNMV | ||
11.01. | LABORATORIOS FARMACEUTICOS ROVI, S.A.: Liquidity contract: transactions conducted in the fourth quarter of 2020 | 4 | CNMV | ||
11.12.20 | Edison Investment Research Limited: Laboratorios Farmacéuticos ROVI (ROVI): All Good Things Come in Threes | 305 | ACCESSWIRE | LONDON, UK / ACCESSWIRE / December 11, 2020 / Laboratorios Farmacéuticos ROVI's (ROVI's) recent capital markets day (CMD) highlighted the strong positioning of its three key franchises. Combined unit... ► Artikel lesen | |
27.11.20 | LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases the results of the PRISMA-3 study of the efficacy and safety of Doria in schizophrenic patients in the journal npj Schizophrenia | 10 | CNMV | ||
24.11.20 | LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases the presentation related to its strategy update because of its 2020 Capital Markets Day. | 7 | CNMV | ||
19.11.20 | ROVI's Target Price To Rise By 6.5 €/shr To 36 €/shr After Moderna Announces Effectiveness Of Its Vaccine | 64 | thecorner.eu | ||
11.11.20 | Laboratorios Farmaceuticos ROVI - Momentum continues across key franchises | 228 | Edison Investment Research | Reported 9M20 numbers highlight continual strength in sales across key franchises and ongoing margin expansion. ROVI reported operating revenue of €302.1m (+12%). Within the low molecular weight heparin... ► Artikel lesen | |
05.11.20 | LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases the presentation related to the first nine months 2020 financial results | 6 | CNMV | ||
20.10.20 | UPDATE 1-Spain's Rovi plans to start manufacturing Moderna vaccine 'very soon' | 25 | Reuters.com | ||
20.10.20 | Spain's Rovi to start manufacturing Moderna vaccine "very soon" if approved | 14 | Reuters.com | ||
01.10.20 | LABORATORIOS FARMACEUTICOS ROVI, S.A.: Liquidity contract: transactions conducted in the third quarter of 2020 | 2 | CNMV | ||
29.07.20 | Laboratorios Farmacéuticos ROVI - Top-line growth, significant margin expansion | 284 | Edison Investment Research | Laboratorios Farmacéuticos ROVI reported H120 operating revenue of €191.1m (+8% y-o-y), driven by strong growth in heparins (+23% to €104.0m) and in toll manufacturing (+31% to €34.8m), which offset... ► Artikel lesen | |
18.05.20 | Laboratorios Farmacéuticos ROVI - COVID-19 stockpiling positive impact | 354 | Edison Investment Research | Laboratorios Farmacéuticos ROVI (ROVI) reported Q120 operating revenue of €101.0m (+23% y-o-y), driven by strong growth both in the speciality pharmaceutical business (+24% to €88.2m) and in the toll... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 28,515 | +2,81 % | Bald endlich mehr Impfstoff von BioNTech, Pfizer, Moderna, CureVac, AstraZeneca, Johnson & Johnson und Sanofi. Altmaier für Corona-Lockerungen | Am Mittwoch ist es wieder so weit. Bund und Länder kommen erneut zusammen, um über weitere Schritte in der Corona-Pandemie zu beraten. Dabei wird die Lage für die Noch-Kanzlerin Angela Merkel immer... ► Artikel lesen | |
NOVO NORDISK | 59,59 | -1,00 % | NOVO NORDISK A S - 6-K, Report of foreign issuer | ||
SANOFI | 76,15 | -0,10 % | Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members | Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
Paris, France - March 3, 2021 - At its meeting on March 3, 2021, Sanofi's Board of... ► Artikel lesen | |
ASTRAZENECA | 78,66 | -1,22 % | BÖRSE TO GO - ALSO, Astra-Zeneca und Siemens Energy | Der Sell-off setzt sich heute in Asien fort. Alle wichtigen Benchmarks der Region liegen weit im Minus, wobei der Handel in Hongkong am stärksten leidet, nachdem bekannt wurde, dass die Stempelsteuer... ► Artikel lesen | |
STRYKER | 201,15 | -0,91 % | Stryker Corp (SYK) Presents at Cowen Healthcare Broker Conference Call - (Transcript) | ||
TILRAY | 20,875 | -2,50 % | Cannabis Fonds: 9 von 47 Aktien mit einer Performance von über 80% seit Januar 2021 | ||
ABBOTT LABORATORIES | 98,96 | -2,35 % | Abbott (ABT): Umsätze, Gewinne & Dividenden steigen - jetzt zugreifen? >>> BREAKOUT-SETUP <<< | Das Labordiagnostik-Unternehmen Abbott (ABT) wurde bekannt durch Corona-Tests. Die fundamentalen Kennzahlen waren auch vorher schon sehr solide!
Symbol: ABT ISIN: US0028241000
Trendbetrachtung auf... ► Artikel lesen | |
ELI LILLY | 167,40 | -2,33 % | Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment | INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Incyte (INCY) announced positive topline results from the late-stage study of baricitinib for the treatment of adults with severe alopecia... ► Artikel lesen | |
DERMAPHARM | 57,88 | -2,18 % | BioNTech-Partner Dermapharm auf Rekordjagd: Das treibt an | Das SDAX-Unternehmen Dermapharm hat vor Kurzem über finanzielle Auswirkungen der Corona-Impfstoff-Produktion von Comirnaty (BioNTech) berichtet und den Markt positiv überrascht. So soll sich der Umsatzbeitrag... ► Artikel lesen | |
VIATRIS | 11,500 | -3,36 % | US Court Rules In Favour Of AstraZeneca In Symbicort Patent Litigation With Mylan, Kindeva | MAPLEWOOD (dpa-AFX) - AstraZeneca Plc. (AZN.L, AZN) said Wednesday that the US District Court for the Northern District of West Virginia has decided in favour of the company in litigation... ► Artikel lesen | |
ZUR ROSE | 358,75 | -4,27 % | Zur Rose: Mit dieser Kooperation generiert die Versandapotheke neues Wachstumspotenzial | Am 17. August 2020 schloss Zur Rose (WKN: A0Q6J0) die Übernahme von Apotal erfolgreich ab. Bei dieser Akquisition ging es nicht allein darum, einen kleineren Konkurrenten zu schlucken. Zur Rose hatte... ► Artikel lesen | |
GW PHARMACEUTICALS | 178,00 | 0,00 % | GW Pharmaceuticals plc: GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex | - If approved by the European Commission (EC), the label for EPIDYOLEX will expand to include a third indication in Europe -LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:... ► Artikel lesen | |
EDWARDS LIFESCIENCES | 70,32 | -1,47 % | Verhaltene Kauflaune bei Aktie von Edwards Lifesciences | Die Wertschätzung für die Edwards Lifesciences-Aktie hat sich an der Börse heute kaum geändert. Zuletzt zahlten Investoren für die Aktie 83,80 US-Dollar. Die Wertschätzung der privaten und institutionellen... ► Artikel lesen | |
CRESCO LABS | 12,270 | -0,97 % | Cresco Labs Files Shelf Registration for Up to $1 Billion in Financing | ||
IONIS PHARMACEUTICALS | 44,055 | -3,73 % | Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates |